NERV: Minerva Neurosciences, Inc. Stock

by  •  • Comments Off on NERV: Minerva Neurosciences, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 16.29
Enterprise Value ($M) 65.74
Book Value ($M) -36.59
Book Value / Share -5.23
Price / Book -0.45
NCAV ($M) -51.48
NCAV / Share -7.36
Price / NCAV -0.32

Profitability (mra)
Return on Invested Capital (ROIC) -0.66
Return on Assets (ROA) -0.61
Return on Equity (ROE) n/a

Liquidity (mrq)
Quick Ratio 12.58
Current Ratio 12.58

Balance Sheet (mrq) ($M)
Current Assets 35.62
Assets 50.51
Liabilities 87.10
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -23.12
Net Income -30.00
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -14.78
Cash from Investing 0.00
Cash from Financing 19.60

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-09 13G Fmr Llc 7.03
01-18 13G/A Federated Hermes, Inc. 19.32 12.49
07-07 13D Boehringer AG 20.79

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-05-01 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-04-22 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 2) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ T
2024-02-26 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No.1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TR
2024-02-22 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2023-11-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2023-08-01 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2023-05-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-05-02 1,946 2,527 77.01
2024-05-01 5,835 5,288 110.34
2024-04-30 6,533 4,631 141.07
2024-04-29 2,052 5,472 37.50

(click for more detail)

Similar Companies
MYNZ – Mainz Biomed N.V. NATR – Nature's Sunshine Products, Inc.
NBSE – NeuBase Therapeutics, Inc. NEXI – NexImmune, Inc.
NKTR – Nektar Therapeutics


Financial data and stock pages provided by
Fintel.io